The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
Annals of Oncology, 06/26/2012
Clinical Article
Hadji P et al. – Data from these large clinical trials suggest that the potential anticancer activity of zoledronic acid (ZOL) may be most robust in a low–estrogen environment.



